AIMS: Lacosamide (LCM; SPM 927, Vimpat®) is an antiepileptic drug (AED) used as adjunctive treatment for adults with partial-onset seizures. LCM has a different mode of action from traditional sodium channel blocking AEDs in that it selectively enhances slow inactivation of sodium channels without affecting fast inactivation. Initial investigations suggested that LCM might have an additional mode of action by binding to the collapsin response mediator protein 2 (CRMP-2), which is further investigated here. METHODS: LCM binding to native and cloned human CRMP-2 was determined using radioligand binding experiments and surface plasmon resonance measurements. RESULTS: No specific binding of [(3) H]LCM (free concentration 100-1450 nM) to isolated or membrane bound human CRMP-2 expressed in mammalian cell systems and bacteria was observed. Surface plasmon resonance analysis also showed that LCM, over a concentration range of 0.39-100 μM, does not specifically bind to human CRMP-2. CONCLUSION: The diverse drug binding methods employed here are well suited to detect specific binding of LCM to CRMP-2 in the micromolar range, yet the results obtained were all negative. Results of this study suggest that LCM does not specifically bind to CRMP-2.
AIMS: Lacosamide (LCM; SPM 927, Vimpat®) is an antiepileptic drug (AED) used as adjunctive treatment for adults with partial-onset seizures. LCM has a different mode of action from traditional sodium channel blocking AEDs in that it selectively enhances slow inactivation of sodium channels without affecting fast inactivation. Initial investigations suggested that LCM might have an additional mode of action by binding to the collapsin response mediator protein 2 (CRMP-2), which is further investigated here. METHODS:LCM binding to native and cloned humanCRMP-2 was determined using radioligand binding experiments and surface plasmon resonance measurements. RESULTS: No specific binding of [(3) H]LCM (free concentration 100-1450 nM) to isolated or membrane bound humanCRMP-2 expressed in mammalian cell systems and bacteria was observed. Surface plasmon resonance analysis also showed that LCM, over a concentration range of 0.39-100 μM, does not specifically bind to humanCRMP-2. CONCLUSION: The diverse drug binding methods employed here are well suited to detect specific binding of LCM to CRMP-2 in the micromolar range, yet the results obtained were all negative. Results of this study suggest that LCM does not specifically bind to CRMP-2.
Authors: Rahul C Deo; Eric F Schmidt; Abdellah Elhabazi; Hideaki Togashi; Stephen K Burley; Stephen M Strittmatter Journal: EMBO J Date: 2003-12-18 Impact factor: 11.598
Authors: T Takahashi; A Fournier; F Nakamura; L H Wang; Y Murakami; R G Kalb; H Fujisawa; S M Strittmatter Journal: Cell Date: 1999-10-01 Impact factor: 41.582
Authors: Thomas Czech; Jae-Won Yang; Edina Csaszar; Joachim Kappler; Christoph Baumgartner; Gert Lubec Journal: Neurochem Res Date: 2004-12 Impact factor: 3.996
Authors: Berkley A Lynch; Nathalie Lambeng; Karl Nocka; Patricia Kensel-Hammes; Sandra M Bajjalieh; Alain Matagne; Bruno Fuks Journal: Proc Natl Acad Sci U S A Date: 2004-06-21 Impact factor: 11.205
Authors: Pamela Doty; David Hebert; Francois-Xavier Mathy; William Byrnes; James Zackheim; Kelly Simontacchi Journal: Ann N Y Acad Sci Date: 2013-07 Impact factor: 5.691